The Importance of Real-World Evidence in Understanding Influenza Vaccine Effectiveness

Pietro Ferrara, Lorenzo Giovanni Mantovani

DOI: https://doi.org/10.7175/fe.v23i1.1522

Keywords

influenza vaccine; Vaccine effectiveness; Real-world evidence

Full Text

HTML PDF

References

  • Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol 2018; 16: 47-60; https://doi.org/10.1038/nrmicro.2017.118
  • World Health Organization - Regional Office for Europe. Influenza - estimating burden of disease. Available at: https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza (last accessed on January 2022)
  • D’Angiolella LS, Lafranconi A, Cortesi PA, et al. Costs and effectiveness of influenza vaccination: a systematic review. Ann Ist Super Sanita 2018; 54: 49-57; https://doi.org/10.4415/ANN_18_01_10
  • Treanor JJ. Influenza (Including Avian Influenza and Swine Influenza). In: Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (Eighth Edition). W.B. Saunders, 2015: Pages 2000-2024.e6; https://doi.org/10.1016/B978-1-4557-4801-3.00167-3
  • US Centers for Disease Control and Prevention – National Center for Immunization and Respiratory Diseases (NCIRD). How Flu Vaccine Effectiveness and Efficacy are Measured. Available at: https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm (last accessed on January 2022)
  • Balasingam S, Wilder-Smith A. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. Int J Infect Dis 2016; 49: 18-29; https://doi.org/10.1016/j.ijid.2016.05.013
  • Boni MF. Vaccination and antigenic drift in influenza. Vaccine 2008; 26: C8-14; https://doi.org/10.1016/j.vaccine.2008.04.011
  • US Centers for Disease Control and Prevention - National Center for Immunization and Respiratory Diseases (NCIRD). Influenza Vaccines for Older Adults. Advisory Committee on Immunization Practices (ACIP) January 12, 2022
  • Jayasundara K, Soobiah C, Thommes E, et al. Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis. BMC Infectious Diseases 2014; 14: 670; https://doi.org/10.1186/s12879-014-0670-5
  • Tokars JI, Rolfes MA, Foppa IM, et al.. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine 2018; 36: 7331-7; https://doi.org/10.1016/j.vaccine.2018.10.026
  • Flannery B, Fry AM. Comparing Influenza Vaccine Types: The Path Toward Improved Influenza Vaccine Strategies. J Infect Dis 2019; 220: 1237-9; https://doi.org/10.1093/infdis/jiy717
  • Halloran ME, Struchiner CJ, Longini IM. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997; 146: 789-803; https://doi.org/10.1093/oxfordjournals.aje.a009196
  • Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials 2017; 18: 122; https://doi.org/10.1186/s13063-017-1870-2
  • Martini N, Trifirò G, Capuano A, et al. Expert opinion on Real-World Evidence (RWE) in drug development and usage. Pharmadvances 2020; 2: 41-50; https://doi.org/10.36118/pharmadvances.02.2020.01
  • Uyeki TM. High-risk Groups for Influenza Complications. JAMA 2020; 324: 2334; https://doi.org/10.1001/jama.2020.21869
  • Ponticelli D, Madotto F, Conti S, et al. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up. Intern Emerg Med 2021: 1-6; https://doi.org/10.1007/s11739-021-02857-y
  • Ponticelli D, Antonazzo IC, Caci G, et al. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months. J Travel Med 2021; 28: taab173; https://doi.org/10.1093/jtm/taab173
  • Ferrara P, Antonazzo IC, Polosa R. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: A 3-month follow-up-Reply. Intern Emerg Med 2022; 17: 313-14; https://doi.org/10.1007/s11739-021-02911-9
  • US Food and Drug Administration. Real-World Evidence. FDA: 2022. Available at: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence (last accessed on January 2022)
  • Reynolds MW, Bourke A, Dreyer AN. Considerations when evaluating real-world data quality in the context of fitness for purpose. Pharmacoepidemiol Drug Saf 2020; 29: 1316-8; https://doi.org/10.1002/pds.5010
  • Schünemann , Brożek J, Guyatt G, et al. GRADE Handbook. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. Available at: https://gdt.gradepro.org/app/handbook/handbook.html (last accessed on January 2022)

Statistics

Abstract: 103 views
HTML: 61 views
PDF: 39 views

Refbacks

  • There are currently no refbacks.